Overview

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
Phase:
Phase 2
Details
Lead Sponsor:
RXi Pharmaceuticals, Corp.